Affiliations:
1 Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China, 410008;
2 Allergy subspecialty direction, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China, 410008;
3 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China, 410008.
Corresponding Authors: Jie Li, Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Fax: +86 073184327332. E-mail: xylijie@csu.edu.cn
BJ. Zhou and C. Peng contributed equally to this work; *J. Li and X. Chen contributed equally to this work.
Funding sources: This work was supported by funding from Grant No.81974476,82173424, 81673065,81830096, 81773341 by the National Natural Science Foundation of China. This study was also supported by the Program for Introducing Talents of Discipline to Universities (111 Project, No. B20017)
Conflicts of Interest: None declared.
Ethical approval status: This study was approved by the Ethics Review Committee of Xiangya Hospital (ethical approval number:2021030471).
Patient Consent on File:  An Informed consent was obtained from the parent or legal guardian.
Manuscript word count: 586 words
References: 6
Figures and tables: 2
Supplementary figures: 1
Supplementary tables: 3
Attachments: STROBE checklist, research protocol, and statistical analysis plan
Keywords: atopic dermatitis, children, dupilumab, drug response, real-world study